Therapeutic insights from small cell lung cancer (SCLC) mechanistically inform SCCE management, given their shared molecular pathogenesis involving SOX2 overexpression and Rb1/p53 pathway inactivation (41). Here, SOX2 is linked to small cell lung carcinoma.